Sodium borate API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Sodium borate API 1330-43-4?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Sodium borate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Sodium borate
- Synonyms:
- Borax , Sodium borate anhydrous
- Cas Number:
- 1330-43-4
- DrugBank number:
- DB14505
- Unique Ingredient Identifier:
- 8191EN8ZMD
General Description:
Sodium borate is a chemical compound identified by the CAS number 1330-43-4. It is known for its distinct pharmacological properties and applications.
Indications:
This drug is primarily indicated for: No FDA- or EMA-approved therapeutic indications on its own. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Sodium borate undergoes metabolic processing primarily in: No metabolic pathways reported. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Absorption:
The absorption characteristics of Sodium borate are crucial for its therapeutic efficacy: Boric acid is well absorbed from the gastrointestinal tract, open wounds, and serous cavities but displays limited absorption in intact skin . Following intraperitoneal injection in mice, the peak concentration was reached in about 1.0-1.5 hr in the brain whereas the value was 0.5 hr in other tissues . The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Half-life:
The half-life of Sodium borate is an important consideration for its dosing schedule: According to human cases of poisoning, the elimination half-life of boric acid ranges from 13 to 24 hours . This determines the duration of action and helps in formulating effective dosing regimens.
Protein Binding:
Sodium borate exhibits a strong affinity for binding with plasma proteins: No protein binding reported. This property plays a key role in the drug's pharmacokinetics and distribution within the body.
Route of Elimination:
The elimination of Sodium borate from the body primarily occurs through: Regardless the route of administration, boric acid predominantly undergoes rapid renal excretion of >90% of total administered dose as unchanged form. Small amounts are also excreted into sweat, saliva, and feces. Following administration as ointment, urinary excretion of boric acid accounted for only 1% of the administered dose . Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Volume of Distribution:
Sodium borate is distributed throughout the body with a volume of distribution of: Volume of distribution ranges from 0.17 to 0.5 L/kg in humans, where large amounts of boric acid are localized in brain, liver, and kidney . This metric indicates how extensively the drug permeates into body tissues.
Clearance:
The clearance rate of Sodium borate is a critical factor in determining its safe and effective dosage: A case report of acute boric acid poisoning following oral ingestion of 21 g of boric acid presents the total body clearance of 0.99 L/h before hemodialysis . It reflects the efficiency with which the drug is removed from the systemic circulation.
Pharmacodynamics:
Sodium borate exerts its therapeutic effects through: Boric acid exhibits minimal bacteriostatic and antifungal activities . Boric acid is likely to mediate antifungal actions at high concentrations over prolonged exposures . The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Sodium borate functions by: Information regarding the mechanism of action of boric acid in mediating its antibacterial or antifungal actions is limited. Boric acid inhibits biofilm formation and hyphal transformation of _Candida albicans_, which are critical virulence factors . In addition, arrest of fungal growth was observed with the treatment of boric acid . This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Categories:
Sodium borate is categorized under the following therapeutic classes: Anions, Anti-Infective Agents, Boric Acids, Boron Compounds, Electrolytes, Ions, Ophthalmologicals, Sensory Organs. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Sodium borate is a type of Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
